- Home
- SPT vs TMDX Comparison
SPT vs TMDX Comparison
Compare SPT & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- TMDX
- Stock Information
- Founded
- SPT 2010
- TMDX 1998
- Country
- SPT United States
- TMDX United States
- Employees
- SPT N/A
- TMDX N/A
- Industry
- SPT Computer Software: Prepackaged Software
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SPT Technology
- TMDX Health Care
- Exchange
- SPT Nasdaq
- TMDX Nasdaq
- Market Cap
- SPT 799.3M
- TMDX 3.9B
- IPO Year
- SPT 2019
- TMDX 2019
- Fundamental
- Price
- SPT $14.37
- TMDX $119.81
- Analyst Decision
- SPT Buy
- TMDX Buy
- Analyst Count
- SPT 10
- TMDX 11
- Target Price
- SPT $27.70
- TMDX $125.40
- AVG Volume (30 Days)
- SPT 970.1K
- TMDX 955.0K
- Earning Date
- SPT 11-06-2025
- TMDX 10-27-2025
- Dividend Yield
- SPT N/A
- TMDX N/A
- EPS Growth
- SPT N/A
- TMDX 2163.11
- EPS
- SPT N/A
- TMDX 2.02
- Revenue
- SPT $430,795,000.00
- TMDX $531,292,000.00
- Revenue This Year
- SPT $13.01
- TMDX $38.87
- Revenue Next Year
- SPT $11.79
- TMDX $20.70
- P/E Ratio
- SPT N/A
- TMDX $59.68
- Revenue Growth
- SPT 14.79
- TMDX 48.09
- 52 Week Low
- SPT $13.33
- TMDX $55.00
- 52 Week High
- SPT $36.30
- TMDX $169.29
- Technical
- Relative Strength Index (RSI)
- SPT 43.06
- TMDX 56.41
- Support Level
- SPT $13.80
- TMDX $105.00
- Resistance Level
- SPT $15.56
- TMDX $119.36
- Average True Range (ATR)
- SPT 0.66
- TMDX 5.23
- MACD
- SPT 0.03
- TMDX 1.20
- Stochastic Oscillator
- SPT 33.06
- TMDX 94.05
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.